Expert Interview
Discussing Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA, PF-08653944 (MET-097i) For Patients with Obesity
Ticker(s): PFE, LLY, NVOInstitution: University of California at San Diego
- Board-certified Obesity Medicine Physician and Medical Director for the Weight Management Program at UC San Diego Health
- Treats over 100 patients per year with obesity with a variety of methods including surgery, medication, nutrition, behavior, and lifestyle support.
- Clinical interest in metabolism, weight regulation, treatment of obesity and weight-related medical conditions; Research interests include anti-obesity medications, obesity medicine education and bariatric surgery.
At a high level, what was your reaction to the Phase 2b data for Pfizer’s once-monthly injectable GLP-1 RA?
Added By: nick_adminDoes monthly dosing meaningfully change the competitive landscape, in your opinion?
Added By: nick_adminHow would you interpret the magnitude of weight loss seen in Phase 2b relative to:
- Wegovy
- Zepbound
Would you switch stable weekly GLP-1 patients to monthly dosing?
Added By: nick_adminOn a scale of 1–10, how competitive does this asset look in the evolving obesity market?
Added By: nick_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
